Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia

Table 2

Basic characteristics of chronic ITP patients.

Patients	Group	Gender	Age (year)	Platelet	Before treatment APRIL level (ng/ml)	After treatment APRIL level (ng/ml)	Before treatment APRIL MFI	After treatment APRIL MFI
26	CR	F	28	17-265	17.8	8.8	678	495
27	NR	F	22	8-19	15.3	12.3	710	968
28	NR	F	63	13-16	9.8	11.5	668	678
29	CR	F	34	38-143	6.8	6.1	619	678
30	R	M	54	32-88	5.9	6.0	654	668
31	CR	M	58	8-207	11.7	10.8	618	515
32	R	M	31	42-90	5.7	6.6	913	654
33	CR	F	40	12-132	16.9	14.5	1009	599
34	NR	F	51	18-21	14.09	12.1	803	913
35	R	F	68	34-89	7.9	9.4	1381	1009
36	CR	M	45	30-160	8.1	6.3	1245	655
37	NR	F	69	25-29	4.9	12.3	890	1229
38	CR	F	26	25-109	14.03	7.5	646	659
39	NR	F	53	17-23	12.8	13.1	627	774
40	CR	F	26	6-123	17.12	10.8	607	550
41	NR	F	35	3-17	19.86	17.98	753	599
42	CR	M	23	35-294	11.2	7.7	711	576
43	CR	M	46	11-113	5.97	8.9	617	699
44	R	M	22	24-44	7.2	7.5	753	711
45	CR	M	50	23-116	5.26	6.1	721	569
46	R	M	74	48-80	7.09	8.1	655	1245
47	R	M	50	38-87	6.9	6.7	678	721
48	R	M	53	46-90	9.1	8.3	710	655
49	NR	M	27	3-13	4.91	12.9	668	885
50	NR	M	40	15-25	8.57	5.32	619	694

M: male; F: female; CR: complete response; R: response; NR: no response.